(RTTNews) - Tuesday, Cartesian Therapeutics (RNAC) reported additional retreatment data for investigational CAR-T therapy Descartes-08 showing sustained improvements in patients with generalized myasthenia gravis (MG). Descartes-08 is an investigational autologous CAR-T therapy targeting BCMA and is being developed for MG and myositis. In a Phase 2 case series of five patients who received retreatment after symptom recurrence, the mean MG-ADL score improved by 6.6 points at 12 months following retreatment, with a median retreatment interval of 16.6 months. The company reported no new safety signals, with no serious adverse events, cytokine release syndrome or neurotoxicity during retreatment.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.